CAR T-Cell Therapy Roundup – Clinical Oncology News
Clinical Oncology News |
CAR T-Cell Therapy Roundup
Clinical Oncology News Chicago—The field of chimeric antigen receptor (CAR) therapy has been heating up, with the recent approval of Novartis' CAR T-cell therapy tisagenlecleucel (Kymriah) for patients with acute lymphoblastic leukemia (ALL). Other CAR T-cell constructs are … |
